143 related articles for article (PubMed ID: 18990508)
1. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy.
Olsen CC; Welsh J; Kavanagh BD; Franklin W; McCarter M; Cardenes HR; Gaspar LE; Schefter TE
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1414-24. PubMed ID: 18990508
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
3. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases.
Howells CC; Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD; Miften M
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e441-6. PubMed ID: 22682809
[TBL] [Abstract][Full Text] [Related]
4. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
[TBL] [Abstract][Full Text] [Related]
7. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
9. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.
Kavanagh BD; Schefter TE; Cardenes HR; Stieber VW; Raben D; Timmerman RD; McCarter MD; Burri S; Nedzi LA; Sawyer TE; Gaspar LE
Acta Oncol; 2006; 45(7):848-55. PubMed ID: 16982549
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases.
McPartlin A; Swaminath A; Wang R; Pintilie M; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):388-395. PubMed ID: 28871989
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
12. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
13. MRI morphologic alterations after liver SBRT : Direct dose correlation with intermodal matching.
Boda-Heggemann J; Attenberger U; Budjan J; Jahnke A; Jahnke L; Vogel L; Simeonova-Chergou AO; Herskind C; Wenz F; Lohr F
Strahlenther Onkol; 2016 Sep; 192(9):641-8. PubMed ID: 27393400
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Rusthoven KE; Kavanagh BD; Cardenes H; Stieber VW; Burri SH; Feigenberg SJ; Chidel MA; Pugh TJ; Franklin W; Kane M; Gaspar LE; Schefter TE
J Clin Oncol; 2009 Apr; 27(10):1572-8. PubMed ID: 19255321
[TBL] [Abstract][Full Text] [Related]
15. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours.
Petersen JB; Lassen Y; Hansen AT; Muren LP; Grau C; Høyer M
Acta Oncol; 2011 Aug; 50(6):823-8. PubMed ID: 21767180
[TBL] [Abstract][Full Text] [Related]
16. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.
Scorsetti M; Arcangeli S; Tozzi A; Comito T; Alongi F; Navarria P; Mancosu P; Reggiori G; Fogliata A; Torzilli G; Tomatis S; Cozzi L
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):336-42. PubMed ID: 23433800
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.
Nakamura Y; Kimura T; Higaki T; Honda Y; Komoto D; Yamagami T; Iida M; Nagata Y; Honda Y; Aikata H; Chayama K; Awai K
Jpn J Radiol; 2015 Oct; 33(10):627-35. PubMed ID: 26227061
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
19. Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT.
Boda-Heggemann J; Jahnke A; Chan MKH; Ghaderi Ardekani LS; Hunold P; Schäfer JP; Huttenlocher S; Wurster S; Rades D; Hildebrandt G; Lohr F; Dunst J; Wenz F; Blanck O
Strahlenther Onkol; 2018 May; 194(5):414-424. PubMed ID: 29404626
[TBL] [Abstract][Full Text] [Related]
20. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
